This inventor holds 1 USPTO granted patent and 2 EPO patents. Top assignee: Clinical Genomics Pty. Ltd.. Active years: 2014.
Company Filing History:
Years Active: 2014
Title: Jan Kazenwadel: Innovator in Nucleic Acid Markers
Introduction
Jan Kazenwadel is a notable inventor based in Belair, Australia. He has made significant contributions to the field of molecular biology, particularly in the development of nucleic acid markers that can determine predisposition to neoplasms and adenomas. His work is crucial for advancing diagnostic and therapeutic applications in oncology.
Latest Patents
Kazenwadel holds a patent for "Nucleic acid markers for use in determining predisposition to neoplasm and/or adenoma." This invention relates to novel nucleic acid molecules whose expression levels are indicative of the onset and progression of gastrointestinal tract neoplasms, such as adenomas. The patent also covers isolated proteins encoded by these nucleic acid molecules and their derivatives, which are useful in various diagnostic and therapeutic applications, particularly concerning colorectal neoplasms.
Career Highlights
Jan Kazenwadel is associated with Clinical Genomics Pty. Ltd., where he continues to innovate in the field of genetic diagnostics. His work has the potential to significantly impact the early detection and treatment of colorectal cancer, improving patient outcomes.
Collaborations
Kazenwadel collaborates with notable colleagues, including Robert James and Julianne Henry, who contribute to his research efforts and the advancement of their shared goals in the field of genomics.
Conclusion
Jan Kazenwadel's contributions to the development of nucleic acid markers represent a significant advancement in cancer diagnostics. His innovative work continues to pave the way for improved methods of detecting and treating neoplasms.